Terapia biológica en patología pulmonar parte I: generalidades y clasificación parte II: terapias específicas en asma, EPOC, enfermedad pulmonar parinquematosa difusa, cáncer pulmonar
Resumen
El avance de la investigación médica, en los campos de la biología molecular y la ingeniería genética, ha traído consigo el desarrollo de una serie de nuevos medicamentos dirigidos a bloquear diferentes vías de la respuesta inmune celular. La terapia biológica, nombre con el cual se reconoce a estos nuevos medicamentos, ofrece una nueva oportunidad terapéutica para el manejo de enfermedades crónicas progresivas. En las enfermedades pulmonares crónicas como el asma, la enfermedad pulmonar obstructiva crónica (EPOC), la enfermedad pulmonar parenquimatosa difusa (EPPD) y el cáncer de pulmón, el tratamiento con medicamentos biológicos ha aportado importantes avances para comprender con mayor claridad estas enfermedades y en algunos casos gracias a la eficacia de los mismos, mejorar la calidad de vida de los pacientes que las presentan. Debido al número cada vez mayor de medicamentos de terapia biológica y su aplicación terapéutica creciente en enfermedades inflamatorias crónicas y cáncer, creemos necesario revisar su estado actual en el manejo de la patología pulmonar crónica.
Descargas
Lenguajes:
esReferencias bibliográficas
Abbas AK, Lichtman AH. Cellular and molecular immunology. 6th edition. Philadelphia: Saunders; 2009. Acceso Marzo 9, 2010.
Biological Therapy; Disponible en: http://www.ncbi.nlm.nih. gov/mesh?term=biological%20therapy
FDA consumer Health Information/U.S Food and Drug Administration. July 25 2008. Disponible en: www.fda.gov/ consumer/updates/biologics062608.html
Biological Therapies for Cancer, 13 de Junio de 2006, National Cancer Institute. Disponible en: http://www.cancer. gov/clinicaltrials/
EMA Cfmpfhuc-. Guideline on similar biological medicinal products. 2005 [28.04.2011]; Disponible en: http://www.ema. europa.eu/docs/en_GB/document_library/Scientific_guideline/ 2009/09/WC5000
Waldmann T. Mechanisms of immunotherapy. Nature medicine. 2003; (9) 269- 277.
The Leukemia & Lymphoma Society. Emerging Therapies in Leukemia, Lymphoma & Myeloma. Transcripción de teleconferencia. Disponible en: www.leukemia lymphoma.org/ all_page?item_id=557011
Fry TJ, Lankester AC. Cancer Immunotherapy: Will Expanding Knowledge Lead to Success in Pediatric Oncology?. Hematol Oncol Clin N Am. 2010; 24; 109-127.
Eichbaum C, Haefeli WE. Nomenklatur und Einteilung von Biologicals. Therapeutische Umschau. 2011; 68(11) 593-601.
Villa, J. Uso de agentes biológicos en reumatología. Fundación Española de Reumatología: Hospital de Sierralllana. Disponible en: http://www.hospitalsierrallana.com/uploads/ Uso_agentes_biologicos_Reumatologia.pdf
Agustín O. Terapias Biológicas en pediatría actualización. Noviembre de 2009. Nomenclatura; página 5. Disponible en: http://auditoriamedicahoy.net/biblioteca/TERAPIAS%20 BIOLOGICAS.%20ACTUALIZACION.pdf
Campos L, Carroz M, Dell Acqua M, Mendieta M, Milanese P, Viera P. Terapias Biológicas, conceptos generales y participación en el esquema de costos global de medicamentos. Disponible en: http://auditoriamedicahoy.net/biblioteca/ Terapiasbiol%C3%B3gicas.pdf
Horton SC. Biological therapy for rheumatoid arthritis: where are we now? British Journal of Hospital Medicine. 2012; 73 (1) 12-8.
Hausmann OV, Seitz M, Villiger PM, Pichler WJ. The Complex Clinical Picture of Side Effects to Biologicals. Med Clin N Am. 2010; 94: 791-804.
Pichler WJ. Adverse side effects to biological agents. Allergy. 2006; 61(8): 912-20.
AMA. Naming Guidelines: Rules for Coining Names: Naming Biologics. 2011 [04.05.2011]; Disponible en: http://www. ama-assn.org/ama/pub/physician-resources/medicalscience/ united-states-adopted-names-council/naming-guidelines/ naming-biologics.page?
Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature. 1996; 383(6603): 787-93.
Akdis CA, Blaser K. Mechanisms of allergen-specific immunotherapy. Allergy. 2000; 55: 522-530.
Lutterotti A, Roland M. Getting specific: monoclonal antibodies in multiple sclerosis. Lancet Neurology. 2008; 7: 538-47.
Han SJ, Gurvinder K, Yang I, Lim M. Biologic Principles of Immunotherapy for Malignant Gliomas. Neurosurg Clin N Am. 2010;
: 1–16. 21. Rosalén J, Fernandez F, Ceña V, Jordán J. Aplicaciones de la Terapia Génica. OFFARM. 2003; 22(10) 142-150.
Lees CW, Ali AI, Thompson AI, et al. The safety profile of antitumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. Aliment Pharmacol Ther. 2009; 29(3): 286-97.
Krause I, Valesini G, Scrivo R, et al. Autoimmune aspects of cytokine and anticytokine therapies. Am J Med. 2003; 115(5): 390-7.
Mazurek J, Jahnz-Różyk K. The variety of types of adverse side-effects during treatment with biological drugs. Int. Rev. Allergol. Clin. Immunol. Family Med. 2012; 18(1) 34-39.
Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med. 2003; 139: 683-693.
Kassiotis G, Kollias G. TNF and receptors in organ-specific autoimmune disease: multi-layered functioning mirrored in animal models. J Clin Invest. 2001;107:1507-1508.
Taylor A, Verhagen J, Akdis CA, Akdis M. T regulatory cells in allergy and health: a question of allergen specificity and balance. Int Arch Allergy Immunol. 2004; 135: 73-82.
Weiner L. Fuly human therapeutic monoclonal antibodies. Journal of immunotherapy. 2006; 29(1); 1-9.
Schirrmacher V. Tumor vaccine design: concepts, mechanisms and efficacy testing. Int Arch Allerg Immunol. 1995; 108: 340-4.
Weiner LM. Fully human therapeutic monoclonal antibodies. J Immunother. 2006; 29(1); 1-9.
Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med. 2004; 350(21): 2167-2179.
Till SJ, James F, Kayhan NA, Durham S. Mechanisms of immunotherapy. The Journal of Allergy and Clinical Immunology. 2004; 113 (6): 1025-1034
Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001; 108: 184-90.
Bousquet J, Rabe K, Humbert M, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med. 2007; 101: 1483-92.
Holgate ST. Cytokine and anti-cytokine therapy for the treatment of asthma and allergic disease. Cytokine. 2004; 28:152-157.
Catley MC, Coote J, Bari M, Tomlinson KL. Monoclonal antibodies for the treatment of asthma. Pharmacology & Therapeutics. 2011; 132: 333-351.
D’Amato G. Role of anti-IgE monoclonal antibody (omalizumab) in the treatment of bronchial asthma and allergic respiratory diseases. European Journal of Pharmacology. 2006; 533: 302-307.
Adams RJ, Fuhlbrigge A, Guilbert T, Lozano P, Martinez F. Inadequate use of asthma medication in the United States: results of the asthma in America national population survey. J Allergy Clin Immunol. 2002; 110: 58-64.
Weiss K, Sullivan S. The health economics of asthma and rhinitis. Assessing the economic impact. J Allergy Clin Immunol. 2001; 107: 3-8.
Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, Beeh KM, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005; 60: 309-316.
Lang DM, Kavuru MS. Omalizumab: Where does it fit into current asthma management? Cleveland Clinic Journal of Medicine. 2004; 71(3): 251-261.
Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with antiimmunoglobulin E antibody (omalizumab). Pediatrics. 2001; 108: 36.
Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev. 2006; 19(2): CD003559.
Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001; 18: 254-61.
Soler M, Matz J, Townley R, Buhl R, O’Brien J, Fox H, Thirlwell J, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001; 18: 254-261.
Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy. 2005; 60: 302-308.
Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-tosevere) allergic asthma. Allergy. 2004; 59: 701-708.
República de Colombia. Ministerio de la Protección Social. Instituto Nacional de Vigilancia de Medicamentos y Alimentos – INVIMA. Resolución No. 2005013247 del 26 de junio del 2005, Por la cual se concede un Registro Sanitario.
Mauad T, Bel EH, Sterk PJ. Asthma therapy and airway remodeling. J Allergy Clin Immunol. 2007; 120(5): 997-1009.
Erin EM, Leaker BR, Nicholson GC, Tan AJ, Green LM, Neighbour H, et al. The effects of a monoclonal antibody directed against tumor necrosis factor-α in asthma. Am J Respir Crit Care Med. 2006; 174: 753-762.
Berry MA, Hargadon B, Shelley M, Parker D, Shaw DE, Green RH, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med. 2006; 354: 697-708.
Howarth PH, Babu KS, Arshad HS, Lau L, Buckley M, Mc- Connell W, et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax. 2005; 60: 1012-1018.
Guilleminault L, Carré Ph, Beau-Salinas F, Taillé C, Dieudé Ph, Crestani B, et al. Asthma Unmasked With Tumor Necrosis Factor - a - Blocking Drugs. Chest. 2011; 140: 1068-1071.
Edwards C, Polosa R. Study of Infliximab Treatment in Asthma. Am. J. Respir. Crit. Care Med. 2007; 175(2): 196.
Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma. N Engl J Med. 2009; 360: 973-84.
Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (revised 2011) Disponible en: www.goldcopd.org.
Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet. 2012; 379: 1341-51.
Molfino N, Jeffery P. Chronic obstructive pulmonary disease: Histopathology, inflammation and potential therapies. Pulmonary Pharmacology & Therapeutics. 2007; 20: 462-472.
Brusselle G, Joos G, Bracke K. New insights into the immunology of chronic obstructive pulmonary disease. Lancet. 2011; 378: 1015-26.
Hanse Tl, Barnes PJ. New drugs for exacerbations of chronic obstructive pulmonary disease. Lancet. 2009; 374: 744-55.
Cosío B, Núñez B. Nuevas perspectivas terapéuticas farmacológicas en el manejo de la EPOC. Arch Bronconeumol. 2007; 43(4): 27-35.
De Boer W I. Cytokines and Therapy in COPD. A Promising Combination? Chest. 2002; 121: 209S-218S.
Aeberli D, Oertle S, Mauron H, et al. Inhibition of the TNFpathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders. Swiss Med Wkly. 2002; 132(29-30): 414-22.
Rennard SI, Fogarty C, Kelsen S, Long W, Ramsdell J, Allison J, et al. The safety and efficacy of infliximab in moderate-tosevere chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007.175 (9):926-29.
Rennard SI, Fogarty C, Kelsen S, Long W, Ramsdell J, Allison J, et al. The safety and efficacy of infliximab in moderate-tosevere chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175 (9):930-34.
Banerjee A, Koziol-White C, Panettieri RJr. p38 MAPK inhibitors, IKK2 inhibitors, and TNFa inhibitors in COPD. Current Opinion in Pharmacology. 2012; 12: 287-292.
Barnes PJ. Current and future therapies for airway mucus hypersecretion. Novartis Found Symp. 2002; 248: 237-49.
Zheng J-P, Kang J, Huang S-G, et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet. 2008; 371: 2013-18.
Blanchard C, Mishra A, Saito-Akei H, et al. Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT- 354). Clin Exp Allergy. 2005; 35(8): 1096-103.
Gross T, Hunninghake G. Idiopathic pulmonary fibrosis. N Engl J Med. 2001; 345(7): 517-525.
American Thoracic Society, European Respiratory Society: American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002; 165(2): 277-304.
Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/ JRS/ALAT statement: idiopathic pulmonary fibrosis: evidencebased guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183(6): 788-824.
Toby M. Idiopathic Pulmonary Fibrosis: Pathobiology of Novel Approaches to Treatment. Clin Chest Med. 2012; 33(1): 69-83. 74. Antoniou KM, Pataka A, Bouros D, Siafakas NM. Pathogenetic pathways and novel pharmacotherapeutic targets in idiopathic pulmonary fibrosis. Pulmonary Pharmacology & Therapeutics. 2007; 20: 453-461.
Cerri S, Spagnolo P, Luppi F, Richeldi L, Management of Idiopathic Pulmonary Fibrosis. Clin Chest Med. 2012; 33: 85-94.
Maher TM. Pirfenidone in idiopathic pulmonary fibrosis. Drugs Today (Barc). 2010; 46(7): 473-482.
Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377. 2011; (9779): 1760-1769.
Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH. A Preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. NEJM. 1999; 341(17): 1264-1269.
Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, King TE. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2004; 350(2): 125-133.
Spagnolo P, Del Giovane C, Luppi F, Cerri S, Balduzzi S, Walters EH, et al. Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database of Systematic Reviews 2010, Issue 9. Art. No.: CD003134. DOI:10.1002/14651858.CD003134.pub2. 81. Richeldi L, Costabel U, Selman M, Soon Kim D, Hansell DM, Nicholson AG, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011; 365: 1079-87.
Antoniou KM, Mamoulaki M, Malagari K, Kritikos HD, Bouros D, Siafakas NM, et al. Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. Clinical and Experimental Rheumatology. 2007; 25: 23-28.
Hadjinicolaou AV, Nisar MK, Bhagat S, Parfrey H, Chilvers ER, et al. Non-infectious pulmonary complications of newer biological agents for rheumatic diseases a systematic literature review. Rheumatology (Oxford). 2011; 50(12): 2297-2305.
Panopoulos ST, Sfikakis PP. Biological treatments and connective tissue disease associated interstitial lung disease. Current Opinion in Pulmonary Medicine. 2011; 17(5): 362-367.
Ming-Yi H, Shye-Jye T, Kuang-Hui S, Winnie Y. Immunotherapy for Lung Cancers. Journal Of Biomedicine & Biotechnology [doi:10.1155/2011/250860]. (2011, Jan); 1-10.
Hirschowitz E, Yannelli J. Immunotherapy for Lung Cancer. Proc Am Thorac Soc. 2009; 6: 224-232,
Isobe T, Herbst RS, Onn A. Current management of advanced non–small cell lung cancer: targeted therapy. Semin Oncol. 2005; 32: 315-328.
Raez L, Fein S, Podack E. Lung Cancer Immunotherapy. Clinical Medicine & Research. 2005; 3(4): 221-228.
Biological Therapies for Cancer, 13 de Junio de 2006, National Cancer Institute. Disponible en: http://www.cancer.gov/clinicaltrials/
American Cancer Society, Immunotherapy 2012. Disponible en: http://www.cancer.org/Search/index?QueryText=immun otherapy&x=42&y=16
Egria G, Takats A. Monoclonal antibodies in the treatment of lung cancer. The Journal Of Cancer Surgery (EJSO). 2006; 32: 385-394.
Kreitman RJ, Pastan I. Immunotoxins for targeted cancer therapy. Adv
Drug Deliv Rev. 1998; 31(1-2): 53-88.
Henry CJ, Buss MS, Hellstrom I, Hellstrom KE, Brewer WG, Bryan JN, et al. Clinical evaluation of BR96 sFv-PE40 immunotoxin therapy in canine models of spontaneously occurring invasive carcinoma. Clin Cancer Res. 2005; 11(2 Pt 1): 751-5. 95. Lynch Jr TJ, Lambert JM, Coral F, Shefner J, Weu P, Blattler WA. Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin. J Clin Oncol. 1997; 15(2): 723-34.
Zimmermann S, Wels W, Froesch BA, Gerstmayer B, Stahel RA, Zangemeister-Wittke U. A novel immunotoxin recognising the epithelial glycoprotein-2 has potent antitumoural activity on chemotherapy-resistant lung cancer. Cancer Immunol Immunother. 1997; 44(1): 1-9.
Zeng L, Ge D, Lin S, Ge X, Xhong G, Zhu J. Research on radioimmunotherapy of lung cancer in nude mice using lung cancer monoclonal antibody LC-1 combined with Y-90. Chin J Lung Cancer. 2003; 6(4): 258-60.
Harris M. Monoclonal antibodies as therapeutic agents for cancer, Lancet Oncol. 2004; 5: 292-302.
Rayzman V, Scott A. Monoclonal antibodies for cancer therapy. Cancer Forum. 2002; 26: 104-08.
Kim ES, Mauer AM, Tran HT, Liu D, Gladish G, Dicke K. A phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer: final report. Proc Am Soc Clin Oncol. 2003; 22: 642a.
Lynch TJ, Lilenbaum R, Bonomi P, Ansari R, Govindan R, Janne PA, A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 2004; 23: 634a.
Rosell R, Daniel C, Ramlau R, Szczesna A. Constenla M, Mennecier B. Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 2004; 23: 618a.
Lambert J. Drug-conjugated monoclonal antibodies for the treatment of cancer. Current Opinion in Pharmacology. 2005; 5: 543-549.
Scott AM, Renner C. Tumour antigens recognised by antibodies. In: Encyclopaedia of life sciences. Londres: Nature Publishing Group, Macmillan; 2001: 1-7.
Raez LE, Fein S, Podack ER. Lung Cancer Immunotherapy. Clinical Medicine & Research. 2005; 3(4): 221-228.
Hirschowitz EA, Yannelli JR. Immunotherapy for Lung Cancer. Proc Am Thorac Soc. 2009; 6: 224-232.
.png)
